Dr Reddys settles litigation related to its generic buprenorphine and naloxone sublingual film

24 Jun 2022 , 03:54 PM

Dr Reddys Laboratories has entered into a Settlement Agreement with Indivior Inc. and Indivior UK and Aquestive Therapeutics, Inc. (Aquestive). Pursuant to the agreement, the Company will receive payments totalling USD 72 million by 31 March 2024. The said agreement resolves all claims between the parties relating to the Companys generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indiviors and Aquestives patent infringement allegations and the Companys antitrust counterclaims. As part of the settlement, the underlying litigation will be dismissed. Powered by Capital Market – Live News